Ambient AI scribes listen to your consultation and write the clinical note for you. They have moved from novelty to daily tool in a remarkably short time, and until now nobody had good UK numbers on who is using them and what they actually think. A new study in BMJ Health & Care Informatics changes that: a nationwide survey of 1,003 UK GPs, the largest of its kind to date.

The headline: adoption is early but accelerating fast, the time savings are real, and so are the errors; especially in exactly the consultations where accuracy matters most.

Key takeaways

• 14% of surveyed UK GPs already use an ambient AI scribe; another 39% intend to adopt one soon
• 80% of users say documentation time fell; 70% report a lighter cognitive load
• Errors are common: 44% of users find mistakes in 10 to 30% of their AI generated notes
• Error risk climbs in multiparty, complex and non English consultations
• 37% of users do not routinely ask patients for consent
• You remain legally responsible for the record, not the software

What the study looked at

Researchers led by Charlotte Blease surveyed UK GPs through Doctors.net.uk in August 2025, asking about use of ambient AI scribes: background systems that capture the consultation dialogue and generate documentation automatically. Of 1,003 respondents, 141 were current users, and the study drilled into their experience of errors, workflow and consent. The authors are careful to call this an early adopter snapshot rather than a population estimate, since respondents were a convenience sample of digitally engaged GPs.

One product dominated: 86% of users ran Heidi Health. Adoption skewed towards GP partners and principals and larger practices, and away from locums and GPs aged 56 and over; a pattern the authors suggest reflects who has the autonomy and infrastructure to introduce new tools.

The good news: less typing, lighter heads

The efficiency findings are striking for a profession drowning in documentation:

• 80% of users reported spending less time on documentation; 30% said the reduction was large
• 70% reported reduced cognitive load during consultations
• 55% rated the AI generated notes as better than standard documentation, needing only minimal revision

The free text comments echoed the numbers: GPs valued being able to look at the patient instead of the screen. If your working day ends with an hour of unfinished notes, it is not hard to see the appeal.

The catch: errors are routine, and they cluster where it hurts

The same GPs who praised the tools also reported correcting them constantly:

• 44% find errors in 10 to 30% of AI generated documents
• 41% correct nearly all generated documentation in some way
• 32% encounter errors often or always, and 14% have seen errors with significant to critical implications for care

Most errors were judged minor. But their distribution should give every practice pause. Error rates were highest with multiple people in the room (38%), complex medical histories (35%), consultations in languages other than English (31%), speech impairment (21%) and noisy rooms (20%). The authors warn this pattern could feed the inverse care law: the patients who already face communication barriers get the least reliable records.

The practical reading, in the authors’ words, is that this is assisted documentation, not replaced documentation. The time saving comes from editing a structured draft rather than composing from scratch. The moment you stop reading the draft is the moment the risk starts.

Consent: the finding with immediate implications

Only 63% of users routinely sought patient consent before using the scribe. Put the other way, 37% did not; a figure the authors flag as having immediate clinical and regulatory implications. Among GPs who did ask, patients rarely minded: 89% said one in ten patients or fewer declined.

UK guidance on whether consent is strictly required remains unsettled, but the ethics are not: patients can only decline something they know about, and the study found asking costs almost nothing. Australia has already gone further, with its professional regulator writing informed consent for scribe use into the core code of conduct.

The regulatory ground is moving

NHS England issued guidance on ambient scribing products in April 2025, requiring a named clinical safety officer, a data protection impact assessment, proper system integration, compliance with data security and medical device regulation, staff training and ongoing monitoring. By June 2025 its chief clinical information officer was warning organisations to stop using tools not registered as a class I medical device with the MHRA.

One point is not moving at all: responsibility for the accuracy of the record stays with the clinician. Using an AI scribe changes how the note gets written; it does not change whose name is accountable for it.

What this means for your practice

If you are using or considering an ambient AI scribe, this study suggests a short checklist:

1. Treat every AI note as a draft. Read it before you file it, every time.
2. Raise your guard in the known danger zones: interpreters, several voices in the room, long complex histories, noisy rooms. Consider not using the tool at all in some of them.
3. Ask patients, every consultation. Most will say yes; the asking protects the relationship and you.
4. Check your tool’s regulatory status against the NHS England requirements, and know who your clinical safety officer is.
5. Keep an eye on accuracy for specific patient groups, not just overall performance.

Make your AI scribe journey count towards your appraisal

Introducing an ambient AI scribe is a textbook quality improvement activity, and the reflections almost write themselves: what changed in your documentation time, what errors you caught and what you did about them, how patients responded when you asked for consent. If a scribe error ever reaches a patient record with consequences, that belongs in your significant events log with the lessons learned.

If you use gptools for your appraisal toolkit, a few minutes logging that experience as a QIA entry, with this study as your supporting reading, turns your everyday adoption of new technology into strong appraisal evidence. Every doctor’s first year is free, so there is no barrier to starting your log today.

FAQ

What is an ambient AI scribe?
A system that listens to the clinician and patient talking during a consultation and automatically drafts the clinical note, so the clinician edits a draft instead of typing from scratch.

How many UK GPs use AI scribes?
In this August 2025 survey of 1,003 UK GPs, 14% were current users and a further 39% intended to adopt one soon. Because the sample was self selecting, treat these as an early adopter snapshot rather than a national prevalence figure.

Are AI scribes accurate enough for general practice?
Users report the notes are often good, and 55% rate them better than standard documentation. But 44% find errors in 10 to 30% of documents, and error rates rise sharply in multiparty, complex and non English consultations. The safe pattern is to treat every output as a draft requiring verification.

Do I need patient consent to use an AI scribe?
UK requirements are still being clarified, but NHS England guidance places significant governance duties on users, and the ethical case for telling patients is strong. In this study most patients consented when asked; 37% of GP users were not routinely asking.

Who is liable if the AI scribe gets it wrong?
You are. In both the UK and Australia, responsibility for the accuracy of the clinical record stays with the clinician regardless of what tool drafted it.

---

Source: Blease C, Kharko A, Garcia Sanchez C, et al. Ambient AI in primary care: an exploratory mixed methods survey of UK general practitioners. BMJ Health & Care Informatics 2026;33:e101847. Read the full study.

A cultural obsession met a miracle drug met a monopoly price: the bill landed in a health service that had no plan to pay it. A tongue-in-cheek autopsy of the most expensive medicine in NHS history.

---

It is easier to be furious at a person than at a spreadsheet. So when the health service quietly logged its largest annual drug bill in 2025, the national imagination did not reach for “structural underinvestment compounded by monopoly pricing.” It reached for a red carpet. Somewhere between a Met Gala silhouette and a nation of before-and-after photos, thinness stopped being an aesthetic and became a prescription: and it feels satisfying to blame the most photographed woman on Earth for the consequences.

It is, of course, nonsense. A reality star from Calabasas did not personally hollow out a Barnsley A&E. But she makes a convenient face for a phenomenon that is entirely real: a class of drugs so effective, so desired, and so expensive that it has quietly rearranged the arithmetic of British healthcare. The interesting story isn’t the celebrity. It’s what the drugs actually buy, and for how long.

The biggest bill in the building

Mounjaro alone reached roughly £574 million in England across the 2025/26 financial year, making it the single most expensive medicine in NHS history: a title previously held by drugs that treat cancers and rare diseases, not clothing sizes. The manufacturer raised the price by as much as 170% for a month’s supply in September 2025, because a monopoly supplier of the thing everyone wants can do exactly that.

And a pound spent is a pound spent. Every million diverted into appetite hormones is a million not staffing a rota, not shortening a referral queue, not oiling the machinery of an emergency department already treating its four-hour target as folklore. The dominoes are real: thinner staffing, longer waits, an over-reliance on the cheaper end of the workforce to hold a rota together. But dominoes are a distraction. The real question is the one that never makes the headline.

What does £574 million actually buy?

Here is the uncomfortable part, and it’s the part the cheerleaders skate over: the benefit reverses when the drug stops.

This is not a hunch. In the landmark STEP 1 extension, people regained around two-thirds of their lost weight within a year of coming off semaglutide, ending up roughly 5.6% below their starting weight rather than the 17% they’d achieved; the improvements in blood pressure, cholesterol and blood sugar drifted back toward baseline right alongside the pounds. A tirzepatide study in JAMA Internal Medicine found that by week 88, 82.5% of people had regained at least a quarter of the weight they’d lost, with the cardiometabolic gains unwinding in proportion. Oxford researchers put it more bluntly still: patients who lost around 15kg regained close to 10kg in the first year off the drug, at a brisk 0.8kg a month.

In fairness, the real world is a little kinder than the trials. In one dataset of nearly 190,000 patients, more than half had held onto their loss two years after stopping, with total regain in only about a fifth: probably because real patients taper gradually and keep some of the diet-and-exercise scaffolding, rather than being yanked onto a placebo overnight the way trial subjects are.

But look closely, because that reassurance is a trap. The only dependable way to keep the benefit is to keep taking the drug. Which means the £574 million is not a one-off investment that quietly pays for itself in a decade of prevented heart attacks. It is the first instalment of a permanent, compounding subscription. These medicines behave far less like a cure and far more like a statin or a blood-pressure pill: effective precisely as long as you keep paying, for the rest of your life, for an ever-growing population. The NHS has itself planned a rollout stretching over roughly twelve years: an admission, in bureaucratic disguise, that this is not a treatment that ends. It is a fixture.

So the honest answer to “how much of that half-billion becomes lasting health?” is: only the portion belonging to people who never stop. And that portion is not cheaper next year. It is the same eye-watering price, again, plus everyone new who joins the queue.

The case for the drug (which is real, and inconvenient)

None of this makes the drugs a boondoggle. Obesity already costs the NHS somewhere north of £11 billion a year in the diabetes, joint replacements and cardiac events it drags behind it. If keeping millions of people on effective medication genuinely prevents a meaningful slice of that, the maths can work: the same way it works for any chronic-disease drug taken indefinitely.

But that framing is the whole game, and almost nobody says it out loud. The debate is conducted as though this is a heroic one-time intervention, when the economics are those of a lifelong maintenance therapy purchased at monopoly rates. Those are extremely different things to budget for. One is a lump sum. The other is a standing order with no end date and a supplier who has already shown he’ll put the price up.

The two grown-up moves

If this is a subscription rather than a cure, then the per-dose price is not a detail. It is the entire ballgame: the health service will be buying this dose forever.

Negotiate like the biggest customer in the world, because it is one. A national system covering tens of millions is not a supplicant. Outcome-based deals where the taxpayer pays more only when the weight actually stays off; volume commitments; capped budgets: dull instruments, precisely suited to a bill that recurs annually until the end of time.

And let the patent cliff do the heavy lifting. Statins cost pennies today for exactly one reason: competition arrived. Semaglutide is expected to lose exclusivity in the UK around 2028, with generics already surfacing in other markets, and tirzepatide follows around 2032. Nobody sane tells a seriously ill patient to “wait until 2028.” But a system with any strategic patience would prioritise the highest-need patients now and build every budget on the assumption that today’s price is a temporary insult, because it is. Paying a monopoly premium, in perpetuity, for a drug whose cheap generic future is already visible on the calendar, is the most expensive possible way to do a sensible thing.

The verdict

Kim Kardashian did not bankrupt the NHS. A very old obsession with being thin collided with a genuinely brilliant, genuinely extortionate class of medicine, in a system with no coherent plan to pay for a benefit that evaporates the moment the injections stop. The drugs may well be worth it. But they are worth it as a lifelong commitment bought at a fair price: not as a half-billion-pound one-night stand that has to be repeated, at full cost, every single year.

The celebrity was never the problem. She just, as ever, had the better lighting.

 

Quick answer: QOF 2026/27 introduces six new or significantly changed indicators that Practice Managers must prepare for now. DM037 requires all 8 NICE diabetes care processes per patient, HF009 mandates 4-pillar heart failure therapy, OB004 and OB005 replace the Weight Management Enhanced Service with 18 new obesity points, and CD001/CD002 consolidate cardiovascular blood pressure control with a new frailty coding dependency. Vaccination indicators (VI001, VI002, VI003) now include the MMRV vaccine and offer improvement thresholds that reward gains from each practice’s own baseline.

If you are a Practice Manager, QOF Lead, or GP Partner looking for a clear, actionable summary of what is changing in the 2026/27 Quality and Outcomes Framework, this guide walks you through every new indicator, the point values at stake, and the exact register audits you should be running this week.

What is changing in QOF 2026/27?

The QOF 2026/27 framework introduces six new or significantly restructured indicators alongside point reallocations across the existing framework. The headline changes are:

1. DM037 replaces DM012 and demands all 8 NICE diabetes care processes annually
2. HF009 replaces HF003 and HF006, requiring 4-pillar heart failure therapy for HFrEF patients
3. OB004 and OB005 are brand new obesity indicators worth 18 points combined
4. CD001 and CD002 consolidate four older indicators (CHD015, CHD016, STIA014, STIA015) into a single blood pressure framework with frailty exclusions
5. VI001, VI002, VI003 add the MMRV vaccine and introduce improvement thresholds
6. CHOL003 drops from 38 to 20 points, while DM034 and DM035 statin indicators both rise to 8 points each

The total QOF point value for 2026/27 is £227.95, a 1.1% increase from the previous year, although list size adjustments mean the cash value per practice is broadly unchanged.

QOF 2026/27 new indicators at a glance

DM037 explained: the 8 diabetes care processes

DM037 is the indicator most likely to catch unprepared practices out. It requires delivery of all 8 NICE-recommended care processes for patients with Type 2 diabetes, drawn from NICE guideline NG28 and tracked by the National Diabetes Audit.

The 8 NICE diabetes care processes

1. HbA1c measurement
2. Blood pressure measurement
3. Serum cholesterol measurement
4. Serum creatinine and eGFR
5. Urine albumin-to-creatinine ratio (ACR)
6. Foot examination
7. BMI or weight measurement
8. Smoking status recording

This is an all-or-nothing indicator. A patient who receives 7 out of 8 care processes does not count toward your numerator. Only patients completing the full set contribute.

National Diabetes Audit data shows that only around 50 to 55% of Type 2 diabetes patients currently receive all 8 processes. The most commonly missed are urine ACR testing and foot examination, both of which require dedicated appointment actions rather than a single blood draw.

Note that retinal screening is the ninth process tracked by the National Diabetes Audit but is delivered by the national screening programme, not by GP practices. It is not included in DM037.

What Practice Managers should do now for DM037

• Run a search for all diabetic patients missing any of the 8 processes in the last 12 months
• Identify the specific gaps, with urine ACR and foot checks typically the largest
• Ensure your annual diabetes review template captures all 8 processes with extractable SNOMED codes
• Build recall workflows that batch patients by missing process, not by appointment type

HF009 explained: the 4 pillars of heart failure therapy

NICE indicator specification IND317, published in November 2025, maps directly to HF009. The indicator covers patients with heart failure and reduced ejection fraction (HFrEF, defined as left ventricular ejection fraction of 40% or less).

The 4 pillars of HFrEF treatment

1. ACE inhibitor, ARB, or ARNI (sacubitril-valsartan)
2. Beta-blocker licensed for heart failure (bisoprolol, carvedilol, or nebivolol)
3. Mineralocorticoid receptor antagonist (spironolactone or eplerenone)
4. SGLT2 inhibitor (dapagliflozin or empagliflozin)

National data suggests only around 15% of HFrEF patients are currently on all four pillars, which is why the upper threshold has been set at a deliberately achievable 50%. The most commonly missing pillar is the SGLT2 inhibitor, since many patients were stabilised on three drugs before SGLT2 inhibitors entered NICE guidance.

What Practice Managers should do now for HF009

• Search the heart failure register for patients coded with HFrEF specifically
• For each patient, audit how many pillars they are currently prescribed
• Identify patients on 2 or 3 pillars who could be optimised with the addition of a missing class
• Assign the work to your clinical pharmacist or PCN pharmacist as a lead role
• Document any contraindications or intolerances clearly so exception reporting is available

OB004 and OB005 explained: the new obesity indicators

OB004 and OB005 mark the return of obesity to QOF after a one-year gap, replacing the retired Weight Management Enhanced Service. Together they are worth 18 points.

OB004: referral to weight management

OB004 is worth 5 points with thresholds of 10 to 30%. It requires that eligible adults with obesity are offered a referral to a structured weight management programme (Tier 2 community lifestyle services or Tier 3 specialist multidisciplinary services) within 90 days of the BMI being recorded.

NICE guideline NG246 sets the referral criteria, including ethnicity-adjusted BMI thresholds:

• BMI of 30 or above for most adults
• BMI of 27.5 or above for people of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family background

OB005: shared decision-making and pharmacotherapy

OB005 is worth 13 points with thresholds of 50 to 80%. It covers shared decision-making conversations and pharmacotherapy for obesity, including NICE-approved medications such as orlistat, liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Mounjaro).

A key open question for Practice Managers is whether OB005 requires an actual prescription or whether a documented shared decision-making conversation (including a mutual decision not to prescribe) is sufficient. The business rules will clarify this, but the achievability gap between those two interpretations is significant.

What Practice Managers should do now for OB004 and OB005

• Identify your obesity register using both standard and ethnicity-adjusted BMI thresholds
• Map local Tier 2 and Tier 3 weight management referral pathways
• Audit current obesity pharmacotherapy prescribing to identify eligible but untreated patients
• Build a shared decision-making consultation template that records decisions in extractable form
• Compare your 2025/26 Weight Management Enhanced Service income with realistic OB004/OB005 projections

CD001 and CD002 explained: consolidated blood pressure control

CD001 (41 points) and CD002 (20 points) replace four older indicators (CHD015, CHD016, STIA014, STIA015), consolidating cardiovascular blood pressure control into a simpler structure. Both apply to patients aged 79 or under without moderate or severe frailty.

Why frailty coding now matters more than ever

The exact frailty definition is expected to align with the Electronic Frailty Index (eFI):

• Fit: eFI 0 to 0.12
• Mild frailty: 0.13 to 0.24
• Moderate frailty: 0.25 to 0.36
• Severe frailty: above 0.36

Patients with moderate or severe frailty will be excluded from CD001 and CD002, which means poor frailty coding will lose you points in two ways: it includes patients who should be excluded, and it pushes your overall achievement rate down.

What Practice Managers should do now for CD001 and CD002

• Run your eFI calculation if your clinical system supports it
• Audit how many patients on your cardiovascular registers have frailty status coded
• Prioritise frailty coding for patients aged 65 and over on CVD registers
• Brief clinicians that frailty coding is now a QOF income driver, not just a clinical record

Vaccination improvement thresholds: a new mechanism for low-uptake areas

The childhood vaccination indicators (VI001, VI002, VI003) now include the MMRV vaccine (measles, mumps, rubella, varicella) and introduce a second route to points based on improvement from your own 2-year baseline.

From 2026/27, practices earn points through whichever route is higher:

• The traditional achievement thresholds (89 to 96%, 86 to 96%, 81 to 96%), or
• A sliding scale starting 5 percentage points above your practice’s 2-year average

For VI001, the improvement upper threshold is 18 percentage points above baseline. For VI002 it is 23 percentage points. For VI003 it is 30 percentage points.

This is particularly valuable for practices in London and other areas with historically low uptake, where the standard thresholds have been effectively unreachable.

What Practice Managers should do now for vaccinations

• Pull your 2-year vaccination averages for VI001, VI002, and VI003
• Calculate your improvement thresholds
• If the improvement route offers a realistic path that the standard route does not, build a targeted vaccination improvement plan

Other QOF 2026/27 changes Practice Managers need to model

Beyond the new indicators, several existing indicators have changed point allocations:

• CHOL003 drops from 38 to 20 points — a meaningful income reduction for practices that were achieving well
• DM034 (primary prevention statin use) rises from 4 to 8 points
• DM035 (secondary prevention statin use) rises from 2 to 8 points
• NDH003 rises from 18 to 20 points and now includes women with previous gestational diabetes
• AF006 upper threshold increases from 90% to 95%
• STIA007 adds ticagrelor to the antiplatelet medication list
• Asthma register now includes patients from age 5
• COPD register business rules are updated to address under and over-recording identified by audit

QOF 2026/27 preparation checklist for Practice Managers

Frequently asked questions about QOF 2026/27

When does QOF 2026/27 start?

QOF 2026/27 runs from 1 April 2026 to 31 March 2027. Coding against the new indicators should begin from the first day of the contract year.

What is the value of a QOF point in 2026/27?

The value of a QOF point in 2026/27 is £227.95, a 1.1% increase on the previous year. The Contractor Population Index is used to weight this against your registered list size.

How many new QOF indicators are there in 2026/27?

There are six new or significantly restructured QOF indicators in 2026/27: DM037, HF009, OB004, OB005, CD001, and CD002. The three childhood vaccination indicators (VI001, VI002, VI003) have also been updated with MMRV inclusion and improvement thresholds.

What is DM037 in QOF?

DM037 is a new diabetes indicator worth 10 points that requires delivery of all 8 NICE-recommended diabetes care processes (HbA1c, blood pressure, cholesterol, eGFR, urine ACR, foot examination, BMI, and smoking status) to each Type 2 diabetes patient within the QOF year. It is an all-or-nothing indicator.

What does HF009 require?

HF009 requires patients with heart failure and reduced ejection fraction (HFrEF) to be prescribed all 4 pillars of disease-modifying therapy: an ACE inhibitor, ARB or ARNI; a heart failure beta-blocker; a mineralocorticoid receptor antagonist; and an SGLT2 inhibitor. It is worth 12 points with thresholds of 20 to 50%.

Are OB004 and OB005 replacing the Weight Management Enhanced Service?

Yes. The Weight Management Enhanced Service is retired in 2026/27. OB004 (5 points) covers referral to structured weight management, and OB005 (13 points) covers shared decision-making and pharmacotherapy. Whether your practice is financially better or worse off depends on your historical referral volume.

How do the new vaccination improvement thresholds work?

VI001, VI002, and VI003 now offer two routes to points: the traditional achievement thresholds, or a new improvement route that starts 5 percentage points above your practice’s 2-year baseline uptake. Practices receive whichever allocation is higher at year-end.

The bottom line for Practice Managers

The clinical definitions behind every new QOF 2026/27 indicator are already published in NICE guidance. Practices that wait for the v51 business rules and clinical system template updates before starting their register audits will lose 6 weeks of preparation time. The Practice Managers who win in 2026/27 will be those who treat QOF preparation as a year-round data quality and recall planning exercise, not an April rush.

Start with the four register audits listed in the checklist above. Brief your clinical team on the four highest-stakes changes (DM037, HF009, the obesity indicators, and frailty coding for CD001/CD002). Model your projected income against the point reallocations. The work is the same whether the business rules drop tomorrow or in March.

Primary NHS England sources
NHS England — Changes to the GP Contract in 2026/27 (24 February 2026 letter)
NHS England — 2026/27 QOF guidance
NHS England — Statement of Financial Entitlements Directions
NICE clinical guidance
NICE NG28 — Type 2 diabetes in adults: management
NICE NG106 — Chronic heart failure in adults: diagnosis and management
NICE IND317 — Heart failure 4-pillar therapy indicator specification
NICE NG246 — Overweight and obesity management
NICE TA875 — Semaglutide (Wegovy) for managing overweight and obesity
NICE TA1026 — Tirzepatide for managing overweight and obesity
NICE TA664 — Liraglutide (Saxenda) for managing overweight and obesity
NICE TA235 — Orlistat for the treatment of obesity
Audit and data sources
National Diabetes Audit (NHS England)
Electronic Frailty Index (eFI) — Clegg et al., Age and Ageing 2016
Secondary commentary
Queen Mary University of London CEG — QOF 2026/27 changes: what we know so far (PDF)
Management in Practice — Making the most of QOF 2026/27, by Dr Gavin Jamie
Practice Index — A practical view of the QOF 26/27 changes, by Ceri Gardener
Practice Index — 2025/26 QOF summary
Londonwide LMCs — Initial response and analysis: GMS Contract changes 2026/27
Insight Solutions — QOF 2026/27 summary
 

---

This article is for informational purposes only and reflects QOF 2026/27 guidance as published. Practices should refer to the latest official NHS England contract documents and v51 QOF business rules when these are released.

 

 

A BMJ Medicine cohort study of nearly 2 million women aged 40–60 in UK primary care suggests that hormone replacement therapy (HRT) prescribing varies by ethnicity, deprivation, and region. Published in September 2025 and drawing on a decade of electronic health records from the QResearch database, the study found that only about 19% of women in this age group received two or more HRT prescriptions; and that uptake differed markedly across population groups. The finding matters because it points to a familiar problem in general practice and women’s health: access to menopause care is not always experienced equally. For clinicians, commissioners, and practice teams, this is useful appraisal material. It shifts the conversation away from whether HRT matters and toward a harder question: who is able to access evidence-based menopause care consistently, and who is not?

Key Takeaway

Across a cohort of 1.98 million women, fewer than one in five received sustained HRT prescriptions over a 10-year period. Patterns of prescribing were not evenly distributed: differences linked to ethnicity, deprivation, and geographical region raise concern that menopause care may still be shaped by structural inequality as much as by clinical need; even eight years after NICE menopause guidance was published in 2015.

Why This Matters for UK General Practice

• Menopause care is now a major primary care workload area, with growing public awareness and patient expectation.
• Variation in HRT prescribing may reflect barriers in access, consultation quality, continuity, clinician confidence, or service design.
• If prescribing patterns differ systematically by deprivation or ethnicity, practices may need to look beyond individual consultations and examine population-level equity.

Questions for Reflection

• Are menopause consultations equally accessible across different patient groups in primary care?
• Could continuity, appointment access, or local prescribing culture be influencing who receives HRT?
• What would an equity-focused review of menopause care look like in a GP practice or PCN?

Bottom Line

This BMJ Medicine paper is a reminder that good menopause care is not only about having effective treatments. It is also about making sure access to those treatments is fair, timely, and consistent across the population.

Source: Hirst JA, Mtika WM, Coupland C, Dixon S, Hippisley-Cox J, Hillman S. Inequalities in hormone replacement therapy prescribing in UK primary care: population based cohort study. BMJ Medicine 2025;4:e001349. DOI: 10.1136/bmjmed-2025-001349

When Benjamin Franklin asked his contacts in France to send over a mysterious elixir for his gout in the 1760s, he probably did not realise he was ordering a medicine that had already been known, mainly as a poison, for more than a millennium. The concoction, sold as Eau Medicinale by French officer Nicolas Husson, crossed the Atlantic as a fashionable gout cure. What Franklin could not have foreseen is that the same substance would one day appear in the New England Journal of Medicine as a tool for preventing myocardial infarction.

The active ingredient in Husson’s remedy was colchicine, derived from the autumn crocus (Colchicum autumnale). Few medicines in routine UK practice can claim a lineage stretching from ancient Greek botanists to modern cardiology guidelines, but colchicine is one of them.

---

From ‘One-Day Killer’ to Medical Curiosity

The earliest descriptions of colchicum-like plants sit deep in classical literature. Theophrastus, writing in the 4th century BC, described a deadly plant known as ephemeron, literally “the one-day killer” (Theophrastus, Historia Plantarum). By the 1st century AD, Dioscorides had formalised the name kolchikon after the Black Sea region of Colchis (Dioscorides, De Materia Medica). His warnings were unambiguous: used unwisely, colchicum “kills by choking”.

For more than 1,500 years, Western physicians largely followed this advice. Medieval herbals listed colchicum among plants to be admired but not consumed. Renaissance herbalist John Gerard summed it up neatly when he wrote that its roots were “very hurtfull to the stomacke” (Gerard, Herball, 1597).

---

The 18th Century Breakthrough: Eau Medicinale

Colchicum’s reputation shifted dramatically in the late 1700s when Nicolas Husson marketed Eau Medicinale as a secret gout remedy. It sold at a premium, 22 shillings per tiny bottle, and was widely imitated but poorly understood. European physicians debated its contents, suggesting everything from digitalis to white hellebore.

In 1814, Londoner John Want solved the mystery. Using a mix of literature review, analysis, and possibly a little espionage, Want identified colchicum as the active ingredient. His findings reshaped gout management across Europe almost immediately.

A plant long classified as a poison had become one of medicine’s most reliable abortive treatments for gout flares.

---

Why Colchicine Works, and Why It Sometimes Does Not

Colchicine binds to tubulin, preventing microtubule formation. This slows or halts cellular processes that depend on structural scaffolding. For neutrophils, this means impaired migration, reduced endothelial adhesion, and blunted inflammatory signalling. Clinically, this results in anti-inflammatory activity at low doses.

Neutrophils conveniently accumulate colchicine because they express low levels of P-glycoprotein. Other tissues pump it out more effectively, which partly explains why the drug can reduce inflammation without universally causing harm.

However, the mechanism also explains the gastrointestinal side effects familiar to clinicians. Blocking microtubules disrupts cell division in rapidly renewing tissues, particularly the gut and bone marrow. Hence, diarrhoea remains as ancient a side effect as the drug itself.

---

Modern Evidence: From FMF to MI Prevention

Familial Mediterranean Fever

Colchicine’s modern renaissance began in the 1970s when researchers discovered that daily colchicine prevents the attacks of Familial Mediterranean Fever and reduces the risk of secondary amyloidosis (Ozen et al., N Engl J Med, 2016). This marked the transition of colchicine from simple gout treatment to targeted anti-inflammatory therapy.

Acute Gout

Surprisingly, despite centuries of use, high-quality evidence arrived only recently. The AGREE trial (Terkeltaub et al., Arthritis Rheum, 2010) showed that a low-dose regimen (1.8 mg over one hour) was nearly as effective as traditional high-dose therapy while causing fewer adverse effects. This finding rapidly changed practice worldwide.

Pericarditis

Cardiology then embraced colchicine. The ICAP trial (NEJM, 2013) demonstrated that combining colchicine with standard therapy halved recurrence rates in acute pericarditis. This led to its incorporation into ESC guidelines and rapid uptake across Europe.

Coronary Disease

The LoDoCo2 (NEJM, 2020) and COLCOT (NEJM, 2019) trials further broadened interest. Daily low-dose colchicine (0.5 mg) reduced cardiovascular events, including myocardial infarction and stroke, by roughly 23 to 30 percent. These results positioned colchicine as a serious contender in long-term cardiovascular risk reduction.

A once-feared botanical toxin had become a frontline anti-inflammatory drug across multiple specialties.

---

Regulatory Plot Twist: When Safety Creates a Monopoly

For decades, colchicine in the United States existed in a regulatory grey zone. It was widely manufactured, rarely questioned, and astonishingly cheap.

The FDA’s 2006 Unapproved Drugs Initiative changed that. The programme encouraged companies to fund modern studies in exchange for temporary market exclusivity. URL Pharma undertook the necessary research, including pharmacokinetic studies and the AGREE trial, and gained approval for Colcrys in 2009.

Once approved, the FDA ordered all other unapproved colchicine products off the market. Overnight, a ten-cent pill became a five-dollar pill.

The backlash was swift. US senators accused URL Pharma of exploiting regulation to create a monopoly. Analysts estimated that if all gout patients required daily colchicine at the new price, annual costs could exceed 11 billion dollars.

Generics eventually returned after exclusivity expired, but prices have never returned to the pre-2009 level. The episode became a case study in how well-intended policy can distort markets.

In 2020, partly because of such cases, the programme was formally discontinued.

---

The Road Ahead

Colchicine’s journey mirrors the evolution of medicine itself. It has travelled from ancient herbal lore to modern pharmacology, from empirical remedies to targeted anti-inflammatory therapy. Its expanding role in cardiovascular medicine continues to attract attention, and further repurposing trials are underway.

Yet the Colcrys episode remains a lasting reminder that the scientific merit of a drug can be overshadowed by regulatory and economic forces. Poorly designed incentives can restrict patient access to medicines that humanity has relied on for centuries.

For UK doctors, colchicine’s story is more than an interesting historical footnote. It is a window into how policy, economics, and pharmacology intersect, and how even the most familiar medicines can have dramatic backstories.

---

Selected References

• Theophrastus. Historia Plantarum, 4th century BC

• Dioscorides. De Materia Medica, 1st century AD

• Gerard J. The Herball, 1597

• Terkeltaub R et al. AGREE Trial. Arthritis Rheum. 2010

• Ozen S et al. FMF Review. N Engl J Med. 2016

• Imazio M et al. ICAP Trial. N Engl J Med. 2013

• Nidorf SM et al. LoDoCo2 Trial. N Engl J Med. 2020

• Tardif J et al. COLCOT Trial. N Engl J Med. 2019

• FDA Unapproved Drugs Initiative, US HHS, 2006 to 2020

Heart disease remains the leading cause of death globally. Despite advancements in understanding risk factors like high cholesterol and blood pressure, a groundbreaking discovery from Spanish researchers at the National Center for Cardiovascular Research (CNIC) in Madrid has unveiled an unexpected villain: your gut bacteria.

Fifteen years ago, researchers set out to study thousands of Banco Santander employees, hoping to unlock the mysteries behind cardiovascular disease. The results, recently published in the prestigious scientific journal Nature, uncovered a startling link. Scientists found that certain gut bacteria produce a molecule called imidazole propionate (C₆H₈N₂O₂), which directly causes atherosclerosis—the dangerous buildup of fat and cholesterol in arteries that leads to heart attacks and strokes.

A Silent Threat: Widespread Hidden Disease

The comprehensive study involved detailed medical imaging (using CAT and PET scans) of apparently healthy volunteers aged between 40 and 55. Shockingly, 63% showed signs of early-stage atherosclerosis. The culprit behind these hidden dangers turned out to be imidazole propionate, a molecule released by certain gut microbes, including strains from Escherichia, Shigella, and Eubacterium.

This molecule, researchers found, doesn’t just correlate with heart disease—it actively triggers it. Imidazole propionate enters the bloodstream, stimulates inflammation in arteries, and initiates the formation of fatty plaques.

From Molecule to Disease: Confirming the Link

Lead scientist David Sancho explains, “Imidazole propionate induces atherosclerosis on its own. There’s a causal relationship.” Experiments in mice confirmed the findings: animals exposed to the molecule rapidly developed artery-clogging plaques. Crucially, these effects occurred even in mice without elevated cholesterol levels, highlighting a previously unknown inflammatory and autoimmune component of heart disease.

Moreover, approximately one in five human volunteers with active, dangerous forms of atherosclerosis showed elevated levels of imidazole propionate, strengthening the real-world relevance of these findings.

Prevention and New Treatment Possibilities

Thankfully, the discovery isn’t all bad news. Scientists also identified how imidazole propionate interacts with our cells, paving the way for potential treatments. By blocking the molecule’s receptor with an experimental drug, researchers completely prevented disease progression in mice—even on a high-cholesterol diet.

This promising development offers hope for preventing heart disease in humans by targeting gut bacteria directly. Dietary changes also appear beneficial: individuals consuming diets rich in vegetables, fruits, whole grains, fish, and low-fat dairy showed lower imidazole propionate levels.

Broader Implications: Beyond Cholesterol

Swedish biologist Fredrik Bäckhed previously linked high imidazole propionate levels with type 2 diabetes, reinforcing the broader health impact of gut microbes. Independent research from Ruhr University Bochum recently validated these cardiovascular findings, further underscoring their significance.

The research suggests that heart disease isn’t solely driven by traditional factors like cholesterol. Instead, our gut bacteria might silently orchestrate damage even in those who appear healthy.

Future Steps and Continued Research

While the current findings are groundbreaking, further research is essential to pinpoint specific bacterial strains responsible for producing imidazole propionate. Still, scientists are optimistic about the potential to revolutionize heart disease prevention, diagnosis, and treatment.

This groundbreaking study, made possible by thousands of volunteers and significant funding from institutions like the “la Caixa” Foundation and the European Research Council, marks a pivotal moment in cardiovascular medicine. Understanding and managing our gut microbiome could soon become as routine as checking cholesterol levels.

Your gut health might just hold the key to a healthier heart.

References

Sancho, D., Mastrangelo, A., Robles, I., Fuster, V., et al. (2025). Gut microbiota–derived imidazole propionate drives atherosclerosis. Nature. https://www.nature.com/articles/s41586-025-09263-w

Breaking the Cycle of Recurrent UTIs: An Innovative Non-Antibiotic Approach

Recurrent urinary tract infections (rUTIs) are among the most common and frustrating clinical conditions faced by healthcare professionals. Not only do they impair patients’ quality of life, but they also significantly contribute to antibiotic resistance—a growing global health crisis. A recent groundbreaking study published in Probiotics and Antimicrobial Proteins offers promising evidence that a carefully designed non-antibiotic “bundle” treatment can effectively manage rUTIs, drastically reducing antibiotic use while improving patient outcomes.

Tackling the rUTI Challenge

Women suffering from rUTIs often find themselves in a relentless cycle of infections, symptoms, and antibiotics. The overuse of antibiotics is especially concerning due to the rising prevalence of multidrug-resistant organisms. Recognizing this, researchers from the ASFO Santa Maria degli Angeli Hospital in Pordenone, Italy, investigated a multimodal non-antibiotic strategy, targeting both infection prevention and overall patient wellness.

The Non-Antibiotic Bundle: A Holistic Intervention

The study enrolled 47 women experiencing recurrent UTIs, testing a comprehensive six-month intervention that combined:

• Behavioral Changes: Enhanced hydration (minimum 2 liters daily), improved bowel management, and optimized intimate hygiene practices.
• Phytotherapy: Regular consumption of cranberry extract and D-mannose, both known to inhibit bacterial adhesion to urothelial surfaces.
• Probiotics: A combination of oral and vaginal probiotics containing strains such as Lactobacillus, Bifidobacterium, and Saccharomyces boulardii, aimed at restoring healthy vaginal and intestinal microbiota.

Remarkable Results: Reduced Antibiotic Use and Improved Quality of Life

After six months, the results were impressive:

• 76% reduction in urinary tract infections compared to the previous six months.
• Over 90% decrease in antibiotic exposure, significantly minimizing the risk of antimicrobial resistance.
• Significant improvement in chronic symptoms like abdominal discomfort, urinary urgency, and suprapubic pain.
• Enhanced quality of life reported by over 80% of participants.

Clinical Implications: A Paradigm Shift in UTI Management

The findings suggest that a holistic, multimodal strategy can profoundly change the standard approach to managing rUTIs. By focusing on patient education, lifestyle adjustments, and microbiota health rather than solely relying on antibiotics, clinicians have a powerful new tool to combat recurrent infections.

Moving Forward

Although this initial study had a modest sample size, the outcomes strongly support further large-scale trials. By reducing antibiotic dependence, healthcare providers can not only manage rUTIs more effectively but also contribute to global antibiotic stewardship efforts.

This study represents an important step toward a future where non-antibiotic solutions play a central role in infectious disease management. It’s time to shift our clinical focus towards strategies that not only address symptoms but also promote long-term health and resilience against infections.

Reference:
Venturini, S., Reffo, I., Avolio, M. et al. (2024). The Management of Recurrent Urinary Tract Infection: Non-Antibiotic Bundle Treatment. Probiotics & Antimicro. Prot., 16, 1857–1865. https://doi.org/10.1007/s12602-023-10141-y

CHOL001 and CHOL002 are no longer in the Quality and Outcomes Framework. From April 2024 they were replaced by CHOL003 and CHOL004, and for 2025/26 these two indicators became some of the highest-point earners in the entire QOF. Between them they now carry 82 points, more than any other clinical area in the framework.

This post is a clean reference for UK general practice teams: what the indicators measure, the new LDL and non-HDL thresholds, points and payment thresholds, exception reporting rules, and the small but important changes that landed for 2025/26.

(If you previously read our 2023/24 cholesterol indicators post on CHOL001 and CHOL002, this post replaces it for current practice.)

---

Quick summary

The headline change is the points uplift. CHOL004 alone is worth 44 points in 2025/26, up from 16. That makes cholesterol target achievement the single most valuable clinical indicator in QOF.

---

What changed when CHOL001 became CHOL003

The wording of the statin-prescribing indicator was kept almost identical when CHOL001 was renumbered to CHOL003 for 2024/25. The register population is the same: patients on the CHD, PAD, Stroke/TIA or CKD registers. Patients with diabetes on these registers are still excluded (they sit under DM034/DM035 instead).

The substantive 2025/26 change is small but worth knowing:

• Icosapent ethyl was removed from the list of acceptable alternative lipid-lowering therapies. Bempedoic acid, ezetimibe, inclisiran and PCSK9 inhibitors remain valid alternatives where a statin is declined or unsuitable, but only where there is a documented adverse reaction to a statin.

Everything else in CHOL003 carries over from CHOL001:

• Patients on the palliative care register are excepted.
• Codes for maximum tolerated lipid-lowering therapy, adverse reaction, not indicated/contraindicated or declined trigger personalised care adjustments (PCA).
• Patients registered in the last three months of the QOF year are excepted.
• Two invites at least seven days apart can also trigger an exception.

---

What changed when CHOL002 became CHOL004, and why it matters more

CHOL004 is the indicator that needs careful attention because the rules have meaningfully shifted.

1. LDL is now the primary measurement

In 2023/24, CHOL002 looked for non-HDL first, and only if that wasn’t recorded would it check LDL. From 2024/25, CHOL004 reverses this: LDL is the primary test, and non-HDL is only checked if no LDL reading exists. For 2025/26 the wording clarifies that if multiple readings exist on the latest date, LDL takes priority.

This is the change most likely to catch practices out. If your local lab still reports non-HDL as a default and your templates don’t prompt for LDL, you may have patients with non-HDL at target who fall outside the indicator because LDL was never requested.

2. The thresholds have been raised

The shift from exclusive to inclusive matters: a patient on exactly 2.0 mmol/L LDL now passes. This is a slightly easier indicator to achieve in clinical practice, although the upper payment threshold also rose for 2025/26.

3. Payment thresholds have moved

CHOL004 in 2024/25 had a lower threshold of 20% and an upper threshold of 35%. For 2025/26 the upper threshold has been raised to 50%, with 20% still the lower bound. Coupled with the rise from 16 to 44 points, this is where the real income shift is.

4. Exception reporting expanded

For 2024/25 onwards, exception reports that previously only applied to CHOL003 (statin prescribing) now also apply to CHOL004 (cholesterol target). This was a significant relaxation. Practices can now exception-report CHOL004 patients for:

• Declining a cholesterol blood test (with the correct code).
• Invites: two invites at least seven days apart, with the most recent invite after the latest cholesterol blood test. This is in line with HYP008 and DM020.
• Patients with a haemorrhagic stroke, who are now automatically excluded from both cholesterol indicators.
• Patients on maximum tolerated lipid-lowering therapy.
• Adverse reaction codes, not-indicated codes, and informed dissent.
• Registration in the last three months of the QOF year.

The combination of higher thresholds plus broader exception reporting is intended to make CHOL004 genuinely achievable rather than aspirational.

---

Register populations: who counts for which indicator

This is the part that still trips practices up.

CHOL003 register (statin prescribing):

• CHD
• PAD
• Stroke/TIA
• CKD (stage 3-5)
• Excludes patients aged 17+ with diabetes (covered by DM034/DM035)

CHOL004 register (cholesterol target):

• CHD
• PAD
• Stroke/TIA
• Excludes CKD
• Includes patients with diabetes or on the palliative care register if they are also on the CHD, PAD or Stroke/TIA register

So a patient with CKD alone is in scope for CHOL003 but not CHOL004. A patient with diabetes and CHD is excluded from CHOL003 but included in CHOL004. The populations overlap but they are not the same set.

---

Practical workflow for hitting the new thresholds

The CHOL004 uplift to 44 points changes the maths for the whole practice year. A few priorities:

1. Audit your lab requesting. If your CVD review templates default to a non-HDL request, switch them to request LDL where the lab supports it. The indicator now looks at LDL first.

2. Identify patients above target early. Run a search on CHD/PAD/Stroke registers for any patient with LDL >2.0 mmol/L (or non-HDL >2.6 mmol/L where LDL isn’t recorded) in the last 12 months. Treatment titration, recheck, and re-review takes time, start in Q1, not Q4.

3. CKD register is the soft spot for CHOL003. CHD, PAD and stroke patients are usually statinised. CKD patients are statinised less reliably. Target this subgroup at the start of the year.

4. Use the new invite-based exception rule for CHOL004. Two invites at least seven days apart, with the second invite after the most recent cholesterol test, will exception a non-responder. This is the route to recover patients who simply will not attend.

5. Make sure haemorrhagic stroke is correctly coded. These patients are now removed automatically from both indicators, but only if the haemorrhagic-stroke code is on the record.

6. Code the alternatives correctly. Bempedoic acid, ezetimibe, inclisiran and PCSK9 inhibitors only count for CHOL003 if there is also a documented adverse reaction to a statin. Icosapent ethyl no longer counts at all from 2025/26.

---

Bottom line

CHOL003 and CHOL004 are not a small renaming exercise. The thresholds are easier to hit, the exception reporting is broader, and the points have roughly tripled. For most practices, CHOL004 is now the single largest available clinical indicator in QOF, and the practices that organise their lab requesting and recall systems around LDL ≤2.0 mmol/L will do significantly better than those that don’t.

If your CVD review templates, search reports, and invite letters were built around the old CHOL001/CHOL002 rules, they need updating before the end of the QOF year.

---

Sources

• NHS England. Quality and Outcomes Framework guidance for 2024/25. https://www.england.nhs.uk/publication/quality-and-outcomes-framework-guidance-for-2024-25/
• NHS England. Changes to the GP Contract in 2025/26. https://www.england.nhs.uk/publication/changes-to-the-gp-contract-in-2025-26/
• NHS Digital. QOF 2024-25 publication and technical annex. https://qof.digital.nhs.uk/

A Fresh Look at an Old Ally:

Mirtazapine for Insomnia in the Older Adult
(7.5mg superior than 15mg)

https://doi.org/10.1093/ageing/afaf050

---

1. Why This Conversation Won’t Go Away

Anyone running a geriatric clinic knows the nightly battle cry: “Doctor, I just can’t sleep.” Benzodiazepines and so-called “Z-drugs” remain common fixes, yet both families bring cognitive haze, falls, and dependency. For years clinicians have quietly pivoted to low-dose mirtazapine—an antidepressant whose antihistaminic and serotonergic blockade leaves most patients yawning within the hour. Until now, hard data were scarce. The MIRAGE trial, published 26 March 2025, finally puts numbers behind this off-label ritual.

---

2. Trial in One Breath

Design: single-centre, double-blind, randomized, placebo-controlled
Population: 60 community-dwelling adults ≥ 65 y with chronic insomnia (per ICSD-3)
Intervention: mirtazapine 7.5 mg nightly vs identical placebo for 28 days
Primary endpoint: change in Insomnia Severity Index (ISI) from baseline to day 28
Key safety endpoints: any adverse event (AE) and AEs causing discontinuation

---

3. Efficacy: More than a Sedative Fog

After four weeks, ISI scores fell by a mean 6.5 points in the mirtazapine arm versus 2.9 with placebo (p = 0.003). In practical terms, roughly half the treated patients slid from the “clinical insomnia” range into the “sub-threshold” zone. Subjective reports mirrored the index: wake-after-sleep-onset shortened, total sleep time lengthened, and sleep efficiency nudged upward.
Take-home: At 7.5 mg, mirtazapine delivers a clinically meaningful, moderate-to-large improvement—something cognitive behavioural therapy matches but few pills can boast in this age group.

---

4. Safety: The Price of a Quiet Night

No severe AEs surfaced, but tolerability was not trivial. Six of thirty mirtazapine recipients (20 %) quit early because of side-effects—primarily morning grogginess, dizziness, and next-day confusion—versus one in the placebo cohort. Nobody fell or fractured, yet the signal reminds us: histamine blockade plus age-related pharmacokinetics equals prolonged hangover.

---

5. Clinical Pearl—Dose Matters More Than You Think

Why 7.5 mg? At this level, α2-adrenergic auto-receptors are only partially blocked, while H1 and 5-HT2A/C antagonism dominates—key for sleep promotion. Climbing to 15 mg or 30 mg may paradoxically lift noradrenergic tone and lighten sedation, but also raises metabolic baggage (weight gain, lipids). For insomnia, start low, stay low.

---

6. Where Does MIRAGE Fit into the Landscape?

Factor	Mirtazapine 7.5 mg	Z-Drugs	Low-dose Doxepin
Evidence in ≥ 65 y	Now RCT-supported	Sparse, mostly extrapolated	One pivotal RCT
Cognitive impact	Mild, transient	Moderate	Minimal
Fall risk	Possible (orthostasis)	Documented	Minimal
Typical half-life	20–40 h	1–7 h	15 h
Insurance coverage (UK)*	Generic	Generic	Branded (high-cost)

*Formulary differences apply; check local guidance.

---

7. Limitations Worth a Minute of Skepticism

• Single centre – practice patterns and patient profiles may differ outside an academic geriatric clinic.
• Short intervention – 28 days answers “can it work?”, not “does it keep working?”.
• Subjective sleep metrics – polysomnography was not employed; misperception of sleep may inflate gains.
• Modest N – the confidence interval, though statistically tight, still leaves room for over- or under-estimation.

---

8. Putting It into Practice—A Mini Algorithm

1. First-line remains CBT-I. Refer whenever feasible.
2. Rule out mimics. Pain, nocturia, REM behaviour disorder, OSA.
3. If pharmacotherapy is unavoidable:
   • Start mirtazapine 7.5 mg HS.
   • Reassess after two weeks (ISI ≥ 6-point drop is a “response”).
   • At four weeks, taper off if ineffective; continue up to three months if benefit outweighs sedation.
4. Monitor weight, orthostatic BP, and cognition at each visit.
5. Document taper plan to minimise long-term, off-label drift.

---

9. Future Directions—Beyond the Mirage

• Long-range outcomes: Does the ISI advantage persist at six or twelve months?
• Objective sleep metrics: Actigraphy or at-home EEG could clarify true sleep architecture effects.
• Frailty-stratified safety: Are discontinuation rates higher in prefrail or sarcopenic elders?
• Comparative head-to-head: How does mirtazapine fare against low-dose doxepin or lemborexant in this cohort?

---

10. Bottom Line for the 17:00 Ward Round

For older adults wrestling with chronic insomnia, low-dose mirtazapine now carries randomized evidence of benefit, shaving roughly 6–7 ISI points over four weeks. Yet one in five may abandon therapy owing to next-day somnolence or dizziness. Use it prudently, monitor closely, and remember: sedative is not synonymous with benign.

ClinicalTrials.gov Identifier NCT05247697 — Published 26 March 2025.